Clinical TrialsThe company reported positive data from the Phase 2 ACUITY trial of privosegtor in acute optic neuritis, indicating positive safety and efficacy.
Market PositionThe company's estimated market value has increased to $1.56B, with a raised price target of $32 per share.
Regulatory ProgressOculis plans to engage with the FDA to align on a registrational path for AON, indicating progress in their developmental pursuits.